Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 24, Issue 4, Pages 202-208

HIV-1 Tropism Testing and Clinical Management of CCR5 Antagonists: Quebec Review and Recommendations

Cécile Tremblay,1,2 Isabelle Hardy,1,3 Richard Lalonde,4,5 Benoit Trottier,1,5,6 Irina Tsarevsky,5,7 Louis-Philippe Vézina,5,8 Michel Roger,1,3 Mark Wainberg,9,10 and Jean-Guy Baril1,5,11

1Centre hospitalier de l’Université de Montréal, Canada
2Laboratoire de santé publique du Québec, Canada
3HIV Genotyping Program, Canada
4McGill University Health Centre, Canada
5Advisory Committee on the Clinical Management of Persons Living with HIV, Canada
6Clinique médicale l’Actuel, Canada
7Service de lutte contre les infections transmissibles sexuellement et par le sang, ministère de la Santé et des Services sociaux, Canada
8Programme national de mentorat sur le VIH-sida, Canada
9McGill AIDS Centre, Canada
10McGill University, Montreal, Quebec, Canada
11Clinique médicale du Quartier Latin, Canada

Copyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


HIV-1 tropism assays play a crucial role in determining the response to CCR5 receptor antagonists. Initially, phenotypic tests were used, but limited access to these tests prompted the development of alternative strategies. Recently, genotyping tropism has been validated using a Canadian technology in clinical trials investigating the use of maraviroc in both experienced and treatment-naive patients. The present guidelines review the evidence supporting the use of genotypic assays and provide recommendations regarding tropism testing in daily clinical management.